Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190009/S009

OPRA Implant System

Integrum AB · Decision date Aug 14, 2025

FDA DECISIONP190009/S009

What did the FDA approve?

FDA records P190009/S009 as a supplement to PMA P190009, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 14, 2025.

FDA approval order statement

Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P190009
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Orthopedic
Decision date
Aug 14, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P190009/S009
Regulatory pathway
PMA supplement
Applicant
Integrum AB
Product code
PJY
Decision code
APPR
Decision date
Aug 14, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Osseoanchored prostheses for the rehabilitation of transfemoral amputees.

Applicant
Integrum AB
Product code
PJY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190009/S009 received

    Application receipt date recorded by FDA.

  2. P190009/S009 · FDA decision

    Normal 180 Day Track No User Fee

  3. P190009/S006 · Related supplement

    OPRA Implant System, Abutment component

Timeline entries are records held by MedtechLedger for P190009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190009

Product / regulatory recordCompanyPathwayDecision dateSource
Integrum ABPMA supplementNov 20, 2025FDA
Integrum ABPMA supplementFeb 12, 2026FDA
Integrum ABPMA supplementMar 12, 2026FDA
Integrum ABPMA supplementApr 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integrum AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Krokslatts Fabriker 50, Mölndal, SE-431 37

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records